{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:26:43Z","timestamp":1793719603921,"version":"4.6.1"},"reference-count":1012,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacc.2025.11.016","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:06:59Z","timestamp":1773425219000},"page":"2624-2757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":373,"title":["2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia"],"prefix":"10.1016","volume":"87","author":[{"given":"Roger S.","family":"Blumenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gaudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera A.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Blankstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaPrincess C.","family":"Brewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"de Ferranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Gianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty J.","family":"Gluckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen F.","family":"Gradney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma","family":"Isiadinso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Lloyd-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Marrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth S.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie H.","family":"McLain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxmi S.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wudeneh M.","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Orringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar S.","family":"Polonsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony R.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Saseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila A.","family":"Tynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9 D.","family":"Villavaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jacc.2025.11.016_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2025.05.009","article-title":"2025 AHA\/ACC statement on cost\/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Kazi","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2025.11.016_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jacc.2025.06.013","article-title":"2025 ACC\/AHA clinical practice guidelines core principles and development process: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Otto","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacc.2025.11.016_bib3","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jacc.2025.05.006","article-title":"Guidance for incorporating FDA processes into the ACC\/AHA clinical practice guideline methodology: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Jneid","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib6","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib8","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib9","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1559-4572.2009.00054.x","article-title":"Pathogenesis and pathophysiology of the cardiometabolic syndrome","volume":"11","author":"Kirk","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jacc.2025.11.016_bib14","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib15","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1161\/ATVBAHA.123.319932","article-title":"Subclinical atherosclerosis: part 1: what is it? Can it be defined at the histological level?","volume":"44","author":"Kawai","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib17","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib18","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1542\/peds.2009-2546","article-title":"Universal versus targeted blood cholesterol screening among youth: the CARDIAC project","volume":"126","author":"Ritchie","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2025.11.016_bib20","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jacc.2015.07.017","article-title":"Universal screening for familial hypercholesterolemia in children","volume":"66","author":"Klancar","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib21","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-066736","article-title":"Predictors in youth of adult cardiovascular events","volume":"154","author":"Nuotio","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2025.11.016_bib22","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1161\/01.ATV.20.8.1998","article-title":"The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth","volume":"20","author":"McGill","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib23","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.jacc.2019.02.059","article-title":"Familial hypercholesterolemia among young adults with myocardial infarction","volume":"73","author":"Singh","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child-parent familial hypercholesterolemia screening in primary care","volume":"375","author":"Wald","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2019.11.028","article-title":"Reaching detection targets in familial hypercholesterolaemia: comparison of identification strategies","volume":"293","author":"Wald","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib26","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamacardio.2022.2641","article-title":"Trends of elevated low-density lipoprotein cholesterol, awareness, and screening among young adults in the US, 2003-2020","volume":"7","author":"Zhang","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib28","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.2019.4984","article-title":"Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999-2016","volume":"321","author":"Perak","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.2023.8867","article-title":"Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"330","author":"Guirguis-Blake","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib31","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2109191","article-title":"Childhood cardiovascular risk factors and adult cardiovascular events","volume":"386","author":"Jacobs","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib32","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.jacc.2025.11.016_bib33","article-title":"Statins for children with familial hypercholesterolemia","volume":"2019","author":"Vuorio","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib35","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib36","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib37","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.amepre.2018.01.022","article-title":"Awareness of cardiovascular risk factors in U.S. young adults aged 18-39 years","volume":"54","author":"Bucholz","year":"2018","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/M16-0946","article-title":"Screening for dyslipidemia in younger adults: a systematic review for the U.S. Preventive Services Task Force","volume":"165","author":"Chou","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamapediatrics.2021.2046","article-title":"Low-density lipoprotein cholesterol trajectories and prevalence of high low-density lipoprotein cholesterol consistent with heterozygous familial hypercholesterolemia in US children","volume":"175","author":"Zhang","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib40","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21724","article-title":"Pediatric lipid screening prevalence using nationwide electronic medical records","volume":"7","author":"Thompson-Paul","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2020.10.058","article-title":"Adherence with lipid screening guidelines in standard- and high-risk children and adolescents","volume":"232","author":"Berger","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamapediatrics.2023.0763","article-title":"Cost-effectiveness and return on investment of a nationwide case-finding program for familial hypercholesterolemia in children in the Netherlands","volume":"177","author":"Ademi","year":"2023","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib44","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3390\/genes12081168","article-title":"Successful genetic screening and creating awareness of familial hypercholesterolemia and other heritable dyslipidemias in the Netherlands","volume":"12","author":"Zuurbier","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jacc.2025.11.016_bib45","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1016\/j.jacl.2024.03.009","article-title":"Detecting familial hypercholesterolemia: an observational study leveraging mandatory universal pediatric total cholesterol screening in Slovakia","volume":"18","author":"Raslova","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"Suppl 5","key":"10.1016\/j.jacc.2025.11.016_bib46","first-page":"S213","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2025.11.016_bib47","first-page":"29","article-title":"Prevalence of abnormal lipid levels among youths\u2014United States, 1999-2006","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.114.301430","article-title":"Carotid intima-media thickness in children with familial hypercholesterolemia","volume":"114","author":"Kusters","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib49","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.amepre.2009.04.012","article-title":"Blood lipids in children: age-related patterns and association with body-fat indices: Project HeartBeat!","volume":"37","author":"Dai","year":"2009","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib50","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.123.064168","article-title":"Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease","volume":"147","author":"Zhang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib51","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2025.11.016_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.119.002723","article-title":"New case detection by cascade testing in familial hypercholesterolemia: a systematic review of the literature","volume":"12","author":"Lee","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4290","article-title":"Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis","volume":"4","author":"Marks","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jacc.2025.11.016_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/jpc.15700","article-title":"Pilot study of universal screening of children and child-parent cascade testing for familial hypercholesterolaemia in Australia","volume":"58","author":"Martin","year":"2022","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0969141318796856","article-title":"Integration of child-parent screening and cascade testing for familial hypercholesterolaemia","volume":"26","author":"Wald","year":"2019","journal-title":"J Med Screen"},{"key":"10.1016\/j.jacc.2025.11.016_bib59","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","article-title":"Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events","volume":"118","author":"Mora","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib61","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinternmed.2012.3708","article-title":"Fasting time and lipid levels in a community-based population: a cross-sectional study","volume":"172","author":"Sidhu","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib62","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/CIRCULATIONAHA.114.010001","article-title":"Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III)","volume":"130","author":"Doran","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib63","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","article-title":"Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study","volume":"57","author":"Langsted","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib64","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications","volume":"62","author":"Martin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib65","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib66","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28817","article-title":"Comparison of methods to estimate low-density lipoprotein cholesterol in patients with high triglyceride levels","volume":"4","author":"Sajja","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib67","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1373\/clinchem.2004.047001","article-title":"Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations","volume":"51","author":"Blom","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib68","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacl.2007.07.006","article-title":"Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B","volume":"1","author":"Sniderman","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib69","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/CIRCULATIONAHA.117.030677","article-title":"Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy","volume":"137","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib71","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamacardio.2018.1533","article-title":"Comparison of low-density lipoprotein cholesterol assessment by Martin\/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER Trial","volume":"3","author":"Martin","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/clinchem\/48.3.489","article-title":"Performance of four homogeneous direct methods for LDL-cholesterol","volume":"48","author":"Miller","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib73","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib74","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib75","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","volume":"55","author":"Arsenault","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib76","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib77","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(19)32519-X","article-title":"Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium","volume":"394","author":"Brunner","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib78","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib79","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Goff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib80","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib81","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib82","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A test in context: lipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib83","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib84","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib85","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jacc.2015.12.047","article-title":"Fasting or nonfasting lipid measurements: it depends on the question","volume":"67","author":"Driver","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5334\/gh.1214","article-title":"Accuracy of 23 equations for estimating LDL cholesterol in a clinical laboratory database of 5,051,467 patients","volume":"18","author":"Samuel","year":"2023","journal-title":"Glob Heart"},{"key":"10.1016\/j.jacc.2025.11.016_bib87","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/clinchem\/41.10.1414","article-title":"National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement","volume":"41","author":"Bachorik","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100148","article-title":"LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials","volume":"63","author":"Ginsberg","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib89","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/clinchem\/41.10.1427","article-title":"National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement","volume":"41","author":"Warnick","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib90","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4065\/mcp.2010.0058","article-title":"To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?","volume":"85","author":"Lavie","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.11.016_bib91","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib92","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacc.2008.04.052","volume":"52","author":"Ballantyne","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib93","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib94","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacl.2012.04.080","article-title":"Non-high-density lipoprotein cholesterol reporting and goal attainment in primary care","volume":"6","author":"Virani","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib95","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jacl.2008.06.013","article-title":"The importance of non-HDL cholesterol reporting in lipid management","volume":"2","author":"Blaha","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib96","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib97","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jacc.2007.07.045","article-title":"Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease","volume":"50","author":"Mudd","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib98","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1161\/CIRCULATIONAHA.108.809582","article-title":"Advanced lipoprotein testing and subfractionation are clinically useful","volume":"119","author":"Superko","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib99","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1161\/CIRCULATIONAHA.108.819359","article-title":"Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib100","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.jacc.2012.04.067","article-title":"What is the role of advanced lipoprotein analysis in practice?","volume":"60","author":"Robinson","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib101","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jama.298.7.776","article-title":"Clinical utility of different lipid measures for prediction of coronary heart disease in men and women","volume":"298","author":"Ingelsson","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib102","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib103","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib104","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib105","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib106","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstr\u00f6m","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib107","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000759","article-title":"Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials","volume":"3","author":"Thanassoulis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib108","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1161\/01.CIR.0000145660.60487.94","article-title":"Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study","volume":"110","author":"Sattar","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib109","doi-asserted-by":"crossref","first-page":"812","DOI":"10.2337\/diacare.22.5.812","article-title":"Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients","volume":"22","author":"Wagner","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib110","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamacardio.2024.1310","article-title":"Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels","volume":"9","author":"Sayed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib111","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1373\/clinchem.2016.264515","article-title":"Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women","volume":"63","author":"Lawler","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib112","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib113","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jacl.2020.11.010","article-title":"Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis","volume":"15","author":"Gonzales","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib116","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/2047487315569411","article-title":"Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C","volume":"22","author":"Pencina","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib117","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"Mora","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib118","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.117.032463","article-title":"Impact of novel low-density lipoprotein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-C and apolipoprotein B targets in selected worldwide dyslipidemia guidelines","volume":"138","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib119","article-title":"Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines","volume":"7","author":"Quispe","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.11.016_bib121","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","article-title":"Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men","volume":"112","author":"Pischon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib122","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib123","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib124","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib126","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.atherosclerosis.2020.10.059","article-title":"Clinical utility of LPA genetic characterization for primary prevention of atherosclerotic cardiovascular disease","volume":"315","author":"Trinder","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib127","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5551\/jat.65238","article-title":"Harmonization of lipoprotein(a) immunoassays using a serum panel value assigned with the IFCC-endorsed mass spectrometry-based reference measurement procedure as a first step towards apolipoprotein standardization","volume":"32","author":"Miida","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacc.2025.11.016_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib132","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib133","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.11.016_bib134","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib135","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib136","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib138","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib139","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/eurheartj\/ehw046","article-title":"Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib141","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2023.02.003","article-title":"The importance of low-density lipoprotein cholesterol measurement and control as performance measures: a joint clinical perspective from the National Lipid Association and the American Society for Preventive Cardiology","volume":"17","author":"Virani","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib142","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib144","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib145","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib146","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/j.amjmed.2019.04.002","article-title":"Association between lipid testing and statin adherence in the Veterans Affairs Health System","volume":"132","author":"Jia","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib147","first-page":"574","article-title":"Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis","volume":"28","author":"Lemstra","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib148","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjmed.2021.11.011","article-title":"Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification","volume":"135","author":"Rana","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib149","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjcard.2019.12.030","article-title":"Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the Veterans Affairs Healthcare System)","volume":"125","author":"Jia","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib150","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2022.05.003","article-title":"Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center","volume":"16","author":"Tran","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib151","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib152","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","article-title":"Genetic risk, adherence to a healthy lifestyle, and coronary disease","volume":"375","author":"Khera","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib153","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib154","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.121.053730","article-title":"American Heart Association's Life's simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease","volume":"145","author":"Hasbani","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028583","article-title":"Integrating diet screening into routine clinical care: the time is now","volume":"12","author":"Vadiveloo","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib156","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1001\/jama.2012.70830","article-title":"Prevalence of and risk factors for autopsy-determined atherosclerosis among US service members, 2001-2011","volume":"308","author":"Webber","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib157","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib158","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamacardio.2022.5271","article-title":"Association of rare protein-truncating DNA variants in APOB or PCSK9 with low-density lipoprotein cholesterol level and risk of coronary heart disease","volume":"8","author":"Dron","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib159","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/CIRCULATIONAHA.111.073585","article-title":"Ideal cardiovascular health in childhood and cardiometabolic outcomes in adulthood: the Cardiovascular Risk in Young Finns Study","volume":"125","author":"Laitinen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib160","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study","volume":"338","author":"Berenson","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib161","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib162","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2109191","article-title":"Childhood cardiovascular risk factors and adult cardiovascular events","volume":"386","author":"Jacobs","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib163","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib164","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib165","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.112.000761","article-title":"Ideal cardiovascular health in adolescence: effect of lifestyle intervention and association with vascular intima-media thickness and elasticity (the Special Turku Coronary Risk Factor Intervention Project for Children [STRIP] study)","volume":"127","author":"Pahkala","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib166","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023386","article-title":"Moderate- and high-intensity exercise improves lipoprotein profile and cholesterol efflux capacity in healthy young men","volume":"11","author":"Stanton","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib167","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.3390\/jcm11175146","article-title":"Effect of high-intensity strength and endurance training in the form of small circuits on changes in lipid levels in men aged 35-40 years","volume":"11","author":"Ambrozy","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib168","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12944-015-0148-5","article-title":"Effect of short term aerobic exercise on fasting and postprandial lipoprotein subfractions in healthy sedentary men","volume":"14","author":"Sabaka","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib169","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2010.09.023","article-title":"Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial","volume":"161","author":"Gepner","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ypmed.2013.06.008","article-title":"Socioeconomic status and dyslipidemia in Korean adults: the 2008-2010 Korea National Health and Nutrition Examination Survey","volume":"57","author":"Nam","year":"2013","journal-title":"Prev Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib171","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-085035","article-title":"Socioeconomic inequalities and dyslipidaemia in adult population of the Ravansar Non-Communicable Disease Cohort Study: the role of sex and age","volume":"14","author":"Izadi","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib172","article-title":"Associations of socioeconomic status and healthy lifestyle with incidence of dyslipidemia: a prospective Chinese governmental employee cohort study","volume":"10","author":"Li","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib173","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3945\/jn.109.112573","article-title":"Food insecurity is associated with chronic disease among low-income NHANES participants","volume":"140","author":"Seligman","year":"2010","journal-title":"J Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib174","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.5888\/pcd13.150441","article-title":"Dyslipidemia and food security in low-Income US adolescents: National Health and Nutrition Examination Survey, 2003-2010","volume":"13","author":"Tester","year":"2016","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2486\/indhealth.2016-0127","article-title":"Work, sleep, and cholesterol levels of U.S. long-haul truck drivers","volume":"55","author":"Lemke","year":"2017","journal-title":"Ind Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib176","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2020.08.015","article-title":"Shift work, and particularly permanent night shifts, promote dyslipidaemia: a systematic review and meta-analysis","volume":"313","author":"Dutheil","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib177","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12944-024-02267-x","article-title":"The association between neighbourhood walkability and blood lipids: a Canadian population study","volume":"23","author":"Cakmak","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.114810","article-title":"Residential greenness and dyslipidemia risk: dose-response relations and mediation through BMI and air pollution","volume":"217","author":"Wang","year":"2023","journal-title":"Environ Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib179","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.envpol.2019.03.128","article-title":"Residential greenness and blood lipids in urban-dwelling adults: the 33 Communities Chinese Health Study","volume":"250","author":"Yang","year":"2019","journal-title":"Environ Pollut"},{"key":"10.1016\/j.jacc.2025.11.016_bib180","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.2011.1202","article-title":"Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial","volume":"306","author":"Jenkins","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib181","series-title":"Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis","author":"Mensink","year":"2016"},{"key":"10.1016\/j.jacc.2025.11.016_bib182","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1161\/CIR.0000000000000743","article-title":"Dietary cholesterol and cardiovascular risk: a science advisory from the American Heart Association","volume":"141","author":"Carson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib183","first-page":"127","article-title":"A Mediterranean diet and low-fat vegan diet to improve body weight and cardiometabolic risk factors: a randomized, cross-over trial","volume":"41","author":"Barnard","year":"2022","journal-title":"J Am Nutr Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib184","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/nu11020338","article-title":"DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses","volume":"11","author":"Chiavaroli","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.11.016_bib186","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib187","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1093\/eurheartj\/ehad211","article-title":"Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials","volume":"44","author":"Koch","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib188","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib189","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.atherosclerosis.2021.03.024","article-title":"Does variation in serum LDL-cholesterol response to dietary fatty acids help explain the controversy over fat quality and cardiovascular disease risk?","volume":"328","author":"Griffin","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib190","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1161\/CIRCULATIONAHA.118.035225","article-title":"Meta-analysis of randomized controlled trials of red meat consumption in comparison with various comparison diets on cardiovascular risk factors","volume":"139","author":"Guasch-Ferre","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib191","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3945\/ajcn.115.110965","article-title":"Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials","volume":"102","author":"Del Gobbo","year":"2015","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib192","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/69.1.30","article-title":"Cholesterol-lowering effects of dietary fiber: a meta-analysis","volume":"69","author":"Brown","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib193","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib194","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/nu12040991","article-title":"The effects of different degrees of carbohydrate restriction and carbohydrate replacement on cardiometabolic risk markers in humans\u2013a systematic review and meta-analysis","volume":"12","author":"Fechner","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.11.016_bib195","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0140-6736(18)31809-9","article-title":"Carbohydrate quality and human health: a series of systematic reviews and meta-analyses","volume":"393","author":"Reynolds","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib196","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1467-789X.2012.01021.x","article-title":"Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors","volume":"13","author":"Santos","year":"2012","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib197","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nutres.2022.02.001","article-title":"Both low-fat and low-carbohydrate diets reduce triglyceride concentration in subjects with multifactorial chylomicronemia syndrome: a randomized crossover study","volume":"101","author":"Fantino","year":"2022","journal-title":"Nutr Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib198","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib199","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40279-024-02115-z","article-title":"The effect of exercise training on blood lipids: a systematic review and meta-analysis","volume":"55","author":"Smart","year":"2025","journal-title":"Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib201","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1454731","article-title":"The effect of upper- and lower-body exercise on next-day postprandial triglycerides in healthy young men","volume":"15","author":"Zhong","year":"2024","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib202","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib204","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib205","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib206","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12916-023-03093-1","article-title":"Substitution of animal-based with plant-based foods on cardiometabolic health and all-cause mortality: a systematic review and meta-analysis of prospective studies","volume":"21","author":"Neuenschwander","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib207","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jacl.2018.08.005","article-title":"The value of incorporating medical nutrition therapy by a registered dietitian nutritionist in clinical practice","volume":"12","author":"Rhodes","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/1747-0080.12509","article-title":"Effectiveness of dietetic consultation for lowering blood lipid levels in the management of cardiovascular disease risk: a systematic review and meta-analysis of randomised controlled trials","volume":"76","author":"Ross","year":"2019","journal-title":"Nutr Diet"},{"key":"10.1016\/j.jacc.2025.11.016_bib209","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1161\/CIRCULATIONAHA.109.192627","article-title":"Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association","volume":"120","author":"Johnson","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ajcn\/69.4.632","article-title":"Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis","volume":"69","author":"Yu-Poth","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib211","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clnesp.2018.07.001","article-title":"Relationship between intake of fruit separately from vegetables and triglycerides\u2013a meta-analysis","volume":"27","author":"Kodama","year":"2018","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.jacc.2025.11.016_bib212","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3390\/nu14051104","article-title":"The effect of dietary interventions on hypertriglyceridemia: from public health to molecular nutrition evidence","volume":"14","author":"Luna-Castillo","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.11.016_bib213","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib214","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib215","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ajcn\/71.2.412","article-title":"Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms","volume":"71","author":"Parks","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib216","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s13142-015-0353-9","article-title":"Effects on cardiovascular risk factors of weight losses limited to 5-10%","volume":"6","author":"Brown","year":"2016","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib217","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib218","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib219","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib220","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib221","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib222","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.jacl.2024.04.001","article-title":"Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","volume":"18","author":"Bays","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib223","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1093\/eurheartj\/ehad211","article-title":"Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials","volume":"44","author":"Koch","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib224","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib225","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1467-789X.2012.01021.x","article-title":"Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors","volume":"13","author":"Santos","year":"2012","journal-title":"Obes Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib226","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacl.2020.10.005","article-title":"Ketogenic diets, not for everyone","volume":"15","author":"Goldberg","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib227","article-title":"Ketogenic diet benefits to weight loss, glycemic control, and lipid profiles in overweight patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"19","author":"Zhou","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib228","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1017\/S0007114513000548","article-title":"Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials","volume":"110","author":"Bueno","year":"2013","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib229","doi-asserted-by":"crossref","DOI":"10.5888\/pcd21.230347","article-title":"Weight loss in short-term interventions for physical activity and nutrition among adults with overweight or obesity: a systematic review and meta-analysis","volume":"21","author":"Rotunda","year":"2024","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib230","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib231","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib232","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1161\/HYP.0000000000000196","article-title":"Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how? A scientific statement from the American Heart Association","volume":"78","author":"Barone Gibbs","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.11.016_bib233","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","article-title":"Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a Presidential Advisory from the American Heart Association","volume":"146","author":"Lloyd-Jones","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib234","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12944-017-0515-5","article-title":"Effects of aerobic exercise on lipids and lipoproteins","volume":"16","author":"Wang","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib235","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/CIR.0000000000001148","article-title":"Increasing equity of physical activity promotion for optimal cardiovascular health in adults: a scientific statement from the American Heart Association","volume":"147","author":"Jerome","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib236","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1161\/CIR.0000000000001189","article-title":"Resistance exercise training in individuals with and without cardiovascular disease: 2023 update: a scientific statement from the American Heart Association","volume":"149","author":"Paluch","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib237","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12966-019-0797-2","article-title":"The epidemiology of aerobic physical activity and muscle-strengthening activity guideline adherence among 383,928 U.S. adults","volume":"16","author":"Bennie","year":"2019","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jacc.2025.11.016_bib238","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/qjmed\/hcs231","article-title":"Association of physical activity volume and hypercholesterolemia in US adults","volume":"106","author":"Churilla","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.jacc.2025.11.016_bib239","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jmhg.2005.09.003","article-title":"Aerobic exercise and lipids and lipoproteins in men: a meta-analysis of randomized controlled trials","volume":"3","author":"Kelley","year":"2006","journal-title":"J Mens Health Gend"},{"key":"10.1016\/j.jacc.2025.11.016_bib240","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1089\/jwh.2004.13.1148","article-title":"Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials","volume":"13","author":"Kelley","year":"2004","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.jacc.2025.11.016_bib241","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40279-024-02115-z","article-title":"The effect of exercise training on blood lipids: a systematic review and meta-analysis","volume":"55","author":"Smart","year":"2025","journal-title":"Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib242","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/08901171211048135","article-title":"The effects of exclusive walking on lipids and lipoproteins in women with overweight and obesity: a systematic review and meta-analysis","volume":"36","author":"Ballard","year":"2022","journal-title":"Am J Health Promot"},{"key":"10.1016\/j.jacc.2025.11.016_bib243","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.atherosclerosis.2015.10.018","article-title":"The effects of exercise on the lipoprotein subclass profile: a meta-analysis of 10 interventions","volume":"243","author":"Sarzynski","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib244","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912074","article-title":"Effect of exercise on vascular function and blood lipids in postmenopausal women: a systematic review and network meta-analysis","volume":"19","author":"Xin","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/a-1560-6183","article-title":"Resistance training and high-intensity interval training improve cardiometabolic health in high risk older adults: a systematic review and meta-anaylsis","volume":"43","author":"McLeod","year":"2022","journal-title":"Int J Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib246","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib247","doi-asserted-by":"crossref","first-page":"571","DOI":"10.33594\/000000732","article-title":"The effectiveness of physical exercise in reducing common risk factors of atherosclerosis: a systematic review","volume":"58","author":"Alhazmi","year":"2024","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jacc.2025.11.016_bib248","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1249\/MSS.0b013e3182630ec1","article-title":"Initial validation of an exercise \"vital sign\" in electronic medical records","volume":"44","author":"Coleman","year":"2012","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jacc.2025.11.016_bib249","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/08901171211051840","article-title":"Physical activity assessment and promotion in clinical settings in the United States: a scoping review","volume":"36","author":"Grogg","year":"2022","journal-title":"Am J Health Promot"},{"key":"10.1016\/j.jacc.2025.11.016_bib250","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1161\/CIR.0000000000000559","article-title":"Routine assessment and promotion of physical activity in healthcare settings: a Scientific Statement from the American Heart Association","volume":"137","author":"Lobelo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib251","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40279-023-01817-0","article-title":"Estimating the effect of aerobic exercise training on novel lipid biomarkers: a systematic review and multivariate meta-analysis of randomized controlled trials","volume":"53","author":"Wood","year":"2023","journal-title":"Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib252","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40279-013-0110-5","article-title":"Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations","volume":"44","author":"Mann","year":"2014","journal-title":"Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib253","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/oby.2009.384","article-title":"Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect","volume":"17","author":"Kraus","year":"2009","journal-title":"Obesity"},{"key":"10.1016\/j.jacc.2025.11.016_bib254","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1249\/JSR.0000000000000073","article-title":"The effects of exercise training on the traditional lipid profile and beyond","volume":"13","author":"Gordon","year":"2014","journal-title":"Curr Sports Med Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib255","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/healthcare12131309","article-title":"Effects of different aerobic exercises on blood lipid levels in middle-aged and elderly people: a systematic review and bayesian network meta-analysis based on randomized controlled trials","volume":"12","author":"Li","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jacc.2025.11.016_bib256","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033854","article-title":"Effects of different exercise modalities on lipid profile in the elderly population: A meta-analysis","volume":"102","author":"Yun","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2025.11.016_bib257","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7570\/jomes.2019.28.4.278","article-title":"Effects of exercise on the body composition and lipid profile of individuals with obesity: a systematic review and meta-analysis","volume":"28","author":"Kim","year":"2019","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.jacc.2025.11.016_bib258","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib259","series-title":"Physical Activity Guidelines for Americans","year":"2018"},{"key":"10.1016\/j.jacc.2025.11.016_bib260","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib261","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib262","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clnu.2011.11.011","article-title":"Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"31","author":"Kelley","year":"2012","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib263","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1741-7015-9-74","article-title":"Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"9","author":"Kelley","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib264","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4141","article-title":"Prescribing exercise in primary care","volume":"343","author":"Khan","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.11.016_bib266","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1161\/CIR.0000000000001035","article-title":"Supporting physical activity in patients and populations during life events and transitions: a Scientific Statement from the American Heart Association","volume":"145","author":"Lane-Cordova","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2023.102955","article-title":"Effects of curcumin\/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials","volume":"75","author":"Dehzad","year":"2023","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib268","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s41043-024-00608-1","article-title":"Garlic consumption can reduce the risk of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"43","author":"Du","year":"2024","journal-title":"J Health Popul Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib269","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.10.013","article-title":"Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers","volume":"81","author":"Laffin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib270","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.clnu.2023.07.002","article-title":"Omega-3 fatty acid supplements and risk of atrial fibrillation and 'micro-atrial fibrillation': a secondary analysis from the OMEMI trial","volume":"42","author":"Myhre","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib271","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033748","article-title":"Use of dietary supplements among people with atherosclerotic cardiovascular disease in the United States: a population-based analysis from NHANES","volume":"13","author":"Assadourian","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib272","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10408398.2018.1524364","article-title":"Current regulatory guidelines and resources to support research of dietary supplements in the United States","volume":"60","author":"Bailey","year":"2020","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib273","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2008.03.092","article-title":"Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis","volume":"136","author":"Eslick","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib274","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib275","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib276","first-page":"e285","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"73","author":"Virani","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib277","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7762\/cnr.2024.13.1.74","article-title":"Effects of cinnamon supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Fateh","year":"2024","journal-title":"Clin Nutr Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib278","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3390\/nu16101453","article-title":"Safety and efficacy of the consumption of the nutraceutical \"red yeast rice extract\" for the reduction of hypercholesterolemia in humans: a systematic review and meta-analysis","volume":"16","author":"Trogkanis","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.jacc.2025.11.016_bib279","article-title":"The effects of berberine supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis","volume":"9","author":"Zamani","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib280","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jacl.2015.03.012","article-title":"Medical nutrition therapy is the essential cornerstone for effective treatment of \"refractory\" severe hypertriglyceridemia regardless of pharmaceutical treatment: evidence from a lipid management program","volume":"9","author":"Rhodes","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib281","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jacl.2022.06.008","article-title":"Effectiveness of medical nutrition therapy in the management of adult dyslipidemia: a systematic review and meta-analysis","volume":"16","author":"Mohr","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib282","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jacl.2018.06.016","article-title":"Clinical and cost benefits of medical nutrition therapy by registered dietitian nutritionists for management of dyslipidemia: a systematic review and meta-analysis","volume":"12","author":"Sikand","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib283","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11883-023-01096-0","article-title":"Medical nutrition therapy provided by dietitians is effective and saves healthcare costs in the management of adults with dyslipidemia","volume":"25","author":"Sikand","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib284","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11886-020-01397-9","article-title":"Healthcare cost implications of utilizing a dietary intervention to lower LDL cholesterol: proof of concept actuarial analysis and recommendations","volume":"22","author":"Dong","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib286","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib287","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacl.2012.06.005","article-title":"The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis","volume":"6","author":"Brunzell","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib288","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/MED.0000000000000846","article-title":"Multifactorial chylomicronemia syndrome","volume":"31","author":"Chait","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jacc.2025.11.016_bib289","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib290","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib291","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib292","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib293","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib294","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib296","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib297","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib299","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib300","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a Science Advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib302","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib303","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2025.11.016_bib304","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5551\/jat.RV16004","article-title":"Racial differences in the cholesterol-lowering effect of statin","volume":"24","author":"Naito","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacc.2025.11.016_bib305","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib306","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a Scientific Statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib307","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib311","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib312","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib313","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib314","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib315","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib316","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(02)09328-5","article-title":"MRC\/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib317","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib318","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib319","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib320","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib321","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib322","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib323","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib324","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib325","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib326","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib327","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029216","article-title":"Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial","volume":"12","author":"Goodman","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib328","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib329","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib330","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib331","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib332","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib333","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028205","article-title":"US trends in cholesterol screening, lipid levels, and lipid-lowering medication use in US adults, 1999 to 2018","volume":"12","author":"Gao","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib334","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/03007995.2023.2270901","article-title":"Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort","volume":"40","author":"Lahoz","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2025.11.016_bib335","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.amepre.2022.10.010","article-title":"Trends in lipid-lowering prescriptions: increasing use of guideline-concordant pharmacotherapies, U.S., 2017\u20122022","volume":"64","author":"Sekkarie","year":"2023","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib336","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention: time to move the bar","volume":"74","author":"Dixon","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib337","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.123.009988","article-title":"Trends in patient access to and utilization of prescribed PCSK9 inhibitors in a large US claims database from 2015 to 2021","volume":"17","author":"MacDougall","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.11.016_bib338","article-title":"Quantification of utilization management barriers for patients initiating therapy to lower lipid levels","volume":"5","author":"O'Neil","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib339","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib340","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib341","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib342","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib343","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib344","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib345","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13242","article-title":"Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres","volume":"72","author":"Wierzbicki","year":"2018","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacc.2025.11.016_bib346","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacl.2023.05.100","article-title":"Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors","volume":"17","author":"Pinsdorf","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib347","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s43058-021-00135-8","article-title":"Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis","volume":"2","author":"Jones","year":"2021","journal-title":"Implement Sci Commun"},{"key":"10.1016\/j.jacc.2025.11.016_bib348","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib349","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib350","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf472","article-title":"Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease","author":"Zheutlin","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib351","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2109191","article-title":"Childhood cardiovascular risk factors and adult cardiovascular events","volume":"386","author":"Jacobs","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib352","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib353","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib354","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"Cholesterol Treatment Trialists\u2019 Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib355","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019695","article-title":"Does lowering low-density lipoprotein cholesterol with statin restore low risk in middle-aged adults? Analysis of the observational MESA study","volume":"10","author":"Liu","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib356","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0272989X19835239","article-title":"Combining multiple treatment comparisons with personalized patient preferences: a randomized trial of an interactive platform for statin treatment selection","volume":"39","author":"Hopkin","year":"2019","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jacc.2025.11.016_bib357","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017915","article-title":"Shared decisions: a qualitative study on clinician and patient perspectives on statin therapy and statin-associated side effects","volume":"9","author":"Ahmed","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib358","first-page":"CD001431","article-title":"Decision aids for people facing health treatment or screening decisions","volume":"4","author":"Stacey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib359","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jacc.2015.01.043","article-title":"Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC\/AHA guidelines","volume":"65","author":"Martin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib360","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib361","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0661","article-title":"Patient preference distribution for use of statin therapy","volume":"4","author":"Brodney","year":"2021","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib362","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006548","article-title":"Patient-perceived versus actual risk of cardiovascular disease and associated willingness to consider and use prevention therapy","volume":"14","author":"Navar","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.11.016_bib363","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021389","article-title":"Interventions to facilitate shared decision-making using decision aids with patients in primary health care: a systematic review","volume":"99","author":"Coronado-V\u00e1zquez","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2025.11.016_bib364","article-title":"A tool to help patients visualize ASCVD risk and the potential impact of risk-lowering interventions","volume":"15","author":"Mendez","year":"2022","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10.1016\/j.jacc.2025.11.016_bib365","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib366","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"Cholesterol Treatment Trialists\u2019 Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib367","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a Scientific Statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib368","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib369","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jama.2024.13887","article-title":"Statins for primary prevention of cardiovascular disease-with PREVENT, what's a clinician to do?","volume":"332","author":"Khan","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib370","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib371","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib372","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2025.11.016_bib373","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamacardio.2025.2725","article-title":"Statin eligibility according to atherosclerotic cardiovascular Ddsease risk in the US","volume":"10","author":"Khan","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib374","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.jacc.2024.04.030","article-title":"Association of autoimmune diseases with coronary atherosclerosis severity and ischemic events","volume":"83","author":"Mortensen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib375","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib376","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.118.033505","article-title":"Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) coronary calcium atherosclerotic cardiovascular disease risk calculator","volume":"138","author":"Khera","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib377","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib378","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib379","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.291.18.2204","article-title":"Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring","volume":"291","author":"Lloyd-Jones","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib380","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2018.01.014","article-title":"Basic vs more complex definitions of family history in the prediction of coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"93","author":"Patel","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.11.016_bib381","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.atherosclerosis.2020.10.007","article-title":"South Asian ethnicity as a risk factor for coronary heart disease","volume":"315","author":"Pursnani","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib382","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk","volume":"79","author":"Mehta","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib383","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archinte.163.11.1323","article-title":"The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam study","volume":"163","author":"van der Meer","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib384","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Emerging Risk Factors","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib385","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/CIRCULATIONAHA.109.854240","article-title":"Parental occurrence of stroke and risk of stroke in their children","volume":"121","author":"Seshadri","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib386","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013744","article-title":"Excess risk for atherosclerotic cardiovascular outcomes among US adults with HIV in the current era","volume":"9","author":"Rosenson","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib387","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib388","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1093\/eurheartj\/ehaf209","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study","volume":"46","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib389","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2017.06.015","article-title":"Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis","volume":"11","author":"Wong","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib390","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib391","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/ANNALS-24-00716","article-title":"Development and evaluation of a comprehensive prediction model for incident coronary heart disease using genetic, social, and lifestyle\u2013psychological factors: a prospective analysis of the UK biobank","volume":"178","author":"Naderian","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib392","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib393","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib394","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK Biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib395","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib396","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12170-019-0616-y","article-title":"The use of risk enhancing factors to personalize ASCVD risk assessment: evidence and recommendations from the 2018 AHA\/ACC multi-society cholesterol guidelines","volume":"13","author":"Agarwala","year":"2019","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib397","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019589","article-title":"Prognostic utility of risk enhancers and coronary artery calcium score recommended in the 2018 ACC\/AHA multisociety cholesterol treatment guidelines over the Pooled Cohort Equation: insights from 3 large prospective cohorts","volume":"10","author":"Akintoye","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib398","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib399","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007809","article-title":"Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-analysis","volume":"7","author":"Wu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib400","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fendo.2017.00144","article-title":"History of gestational diabetes mellitus in relation to cardiovascular disease and cardiovascular risk factors in US women","volume":"8","author":"Shostrom","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.11.016_bib401","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.003497","article-title":"Preeclampsia and future cardiovascular health","volume":"10","author":"Wu","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2025.11.016_bib402","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib403","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.2337\/dc21-1107","article-title":"Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9,374 postmenopausal women","volume":"44","author":"Yoshida","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib404","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib405","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jama.2022.24093","article-title":"Association between history of adverse pregnancy outcomes and coronary artery disease assessed by coronary computed tomography angiography","volume":"329","author":"Sederholm Lawesson","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib406","article-title":"Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention","volume":"2","author":"Elder","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib407","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(05)67726-4","article-title":"Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study","volume":"366","author":"Ray","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib408","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2014.02.529","article-title":"Pre-eclampsia and future cardiovascular risk among women: a review","volume":"63","author":"Ahmed","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib409","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/CIRCULATIONAHA.119.043429","article-title":"The use of sex-specific factors in the assessment of women\u2019s cardiovascular risk","volume":"141","author":"Agarwala","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib410","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeac065","article-title":"The risk of cardiovascular diseases after miscarriage, stillbirth, and induced abortion: a systematic review and meta-analysis","volume":"2","author":"Kyriacou","year":"2022","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib411","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamacardio.2020.4097","article-title":"Association of adverse pregnancy outcomes with risk of atherosclerotic cardiovascular disease in postmenopausal women","volume":"5","author":"S\u00f8ndergaard","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib412","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072112","article-title":"Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study","volume":"380","author":"Crump","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.11.016_bib413","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.jacc.2020.03.060","article-title":"Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review","volume":"75","author":"Cho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib414","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib415","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1161\/CIRCULATIONAHA.111.034884","article-title":"Birth characteristics and subsequent risks of maternal cardiovascular disease","volume":"124","author":"Bonamy","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib416","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2468-2667(19)30155-0","article-title":"Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data","volume":"4","author":"Zhu","year":"2019","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib417","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1161\/CIR.0000000000001071","article-title":"Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association","volume":"145","author":"Wenger","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib418","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12706","article-title":"Metabolic outcomes in women 6 months and 2 years after preeclampsia versus normotensive pregnancy: a P4 study","volume":"15","author":"Esber","year":"2025","journal-title":"Clin Obes"},{"key":"10.1016\/j.jacc.2025.11.016_bib419","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-020-00864-6","article-title":"The role of sex-specific risk factors in the risk assessment of atherosclerotic cardiovascular disease for primary prevention in women","volume":"22","author":"Freaney","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib420","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/ph17070913","article-title":"Lipoprotein metabolism, dyslipidemia, and lipid-lowering therapy in women: a comprehensive review","volume":"17","author":"Zimodro","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jacc.2025.11.016_bib421","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.hlc.2015.01.004","article-title":"Delivery of a small-for-gestational-age infant and risk of maternal cardiovascular disease \u2013 a population-based record linkage study","volume":"24","author":"Ngo","year":"2015","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2025.11.016_bib422","doi-asserted-by":"crossref","first-page":"S855","DOI":"10.1016\/j.ajog.2017.12.004","article-title":"Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy","volume":"218","author":"McCowan","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2025.11.016_bib423","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1542\/pir.2021-005059","article-title":"Early puberty","volume":"43","author":"Bakhtiani","year":"2022","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib424","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1210\/jcem.87.5.8471","article-title":"Menstrual cycle irregularity and risk for future cardiovascular disease","volume":"87","author":"Solomon","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib425","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ejendo\/lvad077","article-title":"Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria: a prospective population-based cohort study","volume":"189","author":"Ollila","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib426","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1161\/CIR.0000000000000961","article-title":"Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a Scientific Statement from the American Heart Association","volume":"143","author":"Parikh","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib427","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","article-title":"Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants","volume":"54","author":"Aragam","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2025.11.016_bib428","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1038\/s41467-023-42897-w","article-title":"Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments","volume":"14","author":"Busby","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2025.11.016_bib429","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-023-02429-x","article-title":"A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease","volume":"29","author":"Patel","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib430","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/eurheartj\/ehae342","article-title":"Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting","volume":"45","author":"Samani","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib431","article-title":"Integrative polygenic risk score improves the prediction accuracy of complex traits and diseases","volume":"4","author":"Truong","year":"2024","journal-title":"Cell Genom"},{"key":"10.1016\/j.jacc.2025.11.016_bib432","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.123.004272","article-title":"Multi-ancestry polygenic risk score for coronary heart disease based on an ancestrally diverse genome-wide association study and population-specific optimization","volume":"17","author":"Smith","year":"2024","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib433","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003128","article-title":"Interactions between enhanced polygenic risk scores and lifestyle for cardiovascular disease, diabetes, and lipid levels","volume":"14","author":"Ye","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib434","article-title":"Dynamic importance of genomic and clinical risk for coronary artery disease over the life course","volume":"18","author":"Urbut","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib435","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamacardio.2022.4466","article-title":"Predictive utility of a coronary artery disease polygenic risk score in primary prevention","volume":"8","author":"Marston","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib436","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100567","article-title":"Polygenic risk, rare variants, and family history: independent and additive effects on coronary heart disease","volume":"2","author":"Saadatagah","year":"2023","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2025.11.016_bib437","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.ajhg.2022.10.009","article-title":"Systematic comparison of family history and polygenic risk across 24 common diseases","volume":"109","author":"Mars","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacc.2025.11.016_bib438","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.116.024436","article-title":"Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting","volume":"135","author":"Natarajan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib439","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","article-title":"Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib440","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCULATIONAHA.119.043805","article-title":"Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER Trial","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib441","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003459","article-title":"How communicating polygenic and clinical risk for atherosclerotic cardiovascular disease impacts health behavior: an observational follow-up study","volume":"15","author":"Wid\u00e9n","year":"2022","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib442","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2022.100068","article-title":"Clinical implementation of combined monogenic and polygenic risk disclosure for coronary artery disease","volume":"1","author":"Maamari","year":"2022","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2025.11.016_bib443","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.115.020109","article-title":"Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the MI-GENES Clinical Trial)","volume":"133","author":"Kullo","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib444","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/j.jacc.2020.04.027","article-title":"Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease","volume":"75","author":"Aragam","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib445","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jama.2024.23784","article-title":"Evaluating performance and agreement of coronary heart disease polygenic risk scores","volume":"333","author":"Abramowitz","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib446","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41588-021-00961-5","article-title":"Large uncertainty in individual polygenic risk score estimation impacts PRS-based risk stratification","volume":"54","author":"Ding","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2025.11.016_bib447","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/s41467-025-56945-0","article-title":"Instability of high polygenic risk classification and mitigation by integrative scoring","volume":"16","author":"Misra","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2025.11.016_bib448","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib449","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2016.03.022","article-title":"CAC score improves coronary and cv risk assessment above statin indication by ESC and AHA\/ACC primary prevention guidelines","volume":"10","author":"Mahabadi","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib450","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa2208681","article-title":"Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial","volume":"387","author":"Lindholt","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib451","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003186","article-title":"Coronary artery calcium improves risk assessment in adults with a family history of premature coronary heart disease: results from Multiethnic Study of Atherosclerosis","volume":"8","author":"Patel","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib452","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib453","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003528","article-title":"Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients","volume":"9","author":"Valenti","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib454","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jcmg.2012.02.017","article-title":"Mortality rates in smokers and nonsmokers in the presence or absence of coronary artery calcification","volume":"5","author":"McEvoy","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib455","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jcmg.2020.06.048","article-title":"Warranty period of a calcium score of zero: comprehensive analysis from MESA","volume":"14","author":"Dzaye","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib456","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2025.0584","article-title":"Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial","volume":"333","author":"Nerlekar","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib457","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/CIRCULATIONAHA.116.027034","article-title":"Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR Study (Heinz Nixdorf Recall)","volume":"137","author":"Lehmann","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib458","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2023.06.040","article-title":"Association of coronary artery calcium detected by routine ungated CT imaging with cardiovascular outcomes","volume":"82","author":"Peng","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib459","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.011701","article-title":"Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification: the MESA","volume":"14","author":"Mehta","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib460","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1001\/jamacardio.2024.4115","article-title":"Pitavastatin, procollagen pathways, and plaque stabilization in patients with HIV: a secondary analysis of the REPRIEVE randomized clinical trial","volume":"10","author":"Kolossvary","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib461","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019291","article-title":"Coronary artery calcification and plaque characteristics in people living with HIV: a systematic review and meta-analysis","volume":"10","author":"Soares","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib462","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib463","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-025-02673-0","article-title":"The association between the triglyceride-glucose index and vulnerable plaques in patients with type 2 diabetes mellitus: insights from coronary computed tomography angiography","volume":"24","author":"Zhang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.11.016_bib464","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.amjcard.2025.03.005","article-title":"Clinical significance of diabetes in asymptomatic individuals with zero coronary artery calcium score","volume":"245","author":"Yoon","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib465","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacr.2021.04.014","article-title":"Managing incidental findings on thoracic CT: lung findings. A white paper of the ACR Incidental Findings Committee","volume":"18","author":"Munden","year":"2021","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib466","article-title":"Cardiovascular risk and statin eligibility of young adults after an myocardial infarction: partners YOUNG-MI Registry","author":"Singh","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib467","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.38311","article-title":"External validation of the American Heart Association PREVENT cardiovascular disease risk equations","volume":"7","author":"Scheuermann","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib468","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2016.05.084","article-title":"A simple disease-guided approach to personalize ACC\/AHA-recommended statin allocation in elderly people: the BioImage Study","volume":"68","author":"Mortensen","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib469","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7440","article-title":"Association of coronary artery calcium with long-term, cause-specific mortality among young adults","volume":"2","author":"Miedema","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib470","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2021.08.019","article-title":"Modeling the recommended age for initiating coronary artery calcium testing among at-risk young adults","volume":"78","author":"Dzaye","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib471","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jcmg.2017.01.030","article-title":"The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis","volume":"10","author":"Gupta","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib472","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jcmg.2023.03.007","article-title":"Impact of patient visualization of cardiovascular images on modification of cardiovascular risk factors","volume":"16","author":"Whitmore","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10.1016\/j.jacc.2025.11.016_bib473","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2025.0584","article-title":"Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial","volume":"333","author":"Nerlekar","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib474","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib475","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a calcium score equate to secondary prevention?: insights from the multinational CONFIRM Registry","volume":"16","author":"Budoff","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib476","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamacardio.2016.5493","article-title":"Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death","volume":"2","author":"Carr","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib477","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.jacc.2022.02.051","article-title":"Distribution of coronary artery calcium by age, sex, and race among patients 30-45 years old","volume":"79","author":"Javaid","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib478","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcmg.2019.02.005","article-title":"Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC \u22651,000: results from the CAC Consortium","volume":"13","author":"Peng","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib479","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","article-title":"Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis","volume":"2","author":"Malik","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib480","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jcmg.2019.01.014","article-title":"The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT\/EDIC trials","volume":"12","author":"Budoff","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib481","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2024.01.039","article-title":"Measurement and application of incidentally detected coronary calcium: JACC review topic of the week","volume":"83","author":"Parsa","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib482","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1148\/radiol.15142062","article-title":"Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods","volume":"276","author":"Chiles","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2025.11.016_bib483","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/CIRCULATIONAHA.122.062746","article-title":"Incidental coronary artery calcium: opportunistic screening of previous nongated chest computed tomography scans to improve statin rates (NOTIFY-1 Project)","volume":"147","author":"Sandhu","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib484","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcct.2023.10.001","article-title":"Accuracy of incidental visual coronary artery calcium assessment compared with dedicated coronary artery calcium scoring","volume":"17","author":"Raygor","year":"2023","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2025.11.016_bib485","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamacardio.2024.5702","article-title":"Importance of age and sex in carotid artery plaque detection and cardiovascular disease risk","volume":"10","author":"Tattersall","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib486","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ehjci\/jex239","article-title":"Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans","volume":"19","author":"Sillesen","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib487","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jcmg.2023.02.002","article-title":"Advances in coronary computed tomographic angiographic imaging of atherosclerosis for risk stratification and preventive care","volume":"16","author":"Bienstock","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib488","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.121.055340","article-title":"Prevalence of subclinical coronary artery atherosclerosis in the general population","volume":"144","author":"Bergstrom","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib489","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.jcmg.2022.03.010","article-title":"Coronary atherosclerosis in an asymptomatic U.S. population: Miami Heart Study at Baptist Health South Florida","volume":"15","author":"Nasir","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib490","doi-asserted-by":"crossref","first-page":"433","DOI":"10.7326\/M22-3027","article-title":"Subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort","volume":"176","author":"Fuchs","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib491","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ehjci\/jeae115","article-title":"Prospective deep learning\u2013based quantitative assessment of coronary plaque by computed tomography angiography compared with intravascular ultrasound: the REVEALPLAQUE study","volume":"25","author":"Narula","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib492","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1093\/eurheartj\/ehae471","article-title":"Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial","volume":"45","author":"Nurmohamed","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib493","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2023.05.020","article-title":"AI-guided quantitative plaque staging predicts long-term cardiovascular outcomes in patients at risk for atherosclerotic CVD","volume":"17","author":"Nurmohamed","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib494","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(24)00596-8","article-title":"Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study","volume":"403","author":"Chan","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib495","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1093\/eurheartj\/ehad484","article-title":"Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers","volume":"44","author":"Antoniades","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib496","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1093\/eurheartj\/ehad211","article-title":"Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials","volume":"44","author":"Koch","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib497","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-145-1-200607040-00004","article-title":"Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial","volume":"145","author":"Estruch","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib498","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40279-024-02115-z","article-title":"The effect of exercise training on blood lipids: a systematic review and meta-analysis","volume":"55","author":"Smart","year":"2025","journal-title":"Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib499","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib500","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"Cholesterol Treatment Trialists\u2019 Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib501","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib502","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib503","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib504","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib505","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib506","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib507","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib508","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib509","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/eurjpc\/zwae081","article-title":"Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study","volume":"31","author":"Jun","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib510","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib511","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib512","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib513","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"Navarese","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib514","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib515","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib516","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100825","article-title":"The causal-benefit model to prevent cardiovascular events","volume":"3","author":"Kohli-Lynch","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2025.11.016_bib517","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib518","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib519","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/M16-0946","article-title":"Screening for dyslipidemia in younger adults: a systematic review for the U.S. Preventive Services Task Force","volume":"165","author":"Chou","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib520","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib521","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","year":"2010","journal-title":"Am Heart J"},{"issue":"12","key":"10.1016\/j.jacc.2025.11.016_bib522","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.mayocp.2025.01.018","article-title":"Impact of lipid-lowering combination therapy with statins and ezetimibe vs statin monotherapy on the reduction of cardiovascular outcomes: a meta-analysis","volume":"100","author":"Banach","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.11.016_bib523","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib524","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.recesp.2019.10.013","article-title":"Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry","volume":"73","author":"Perez de Isla","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jacc.2025.11.016_bib525","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib526","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jacl.2017.07.008","article-title":"Cardiovascular disease in familial hypercholesterolemia: validation and refinement of the Montreal-FH-SCORE","volume":"11","author":"Paquette","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib527","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","article-title":"Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia","volume":"41","author":"Paquette","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib528","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2020.06.011","article-title":"SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia","volume":"306","author":"Gallo","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib529","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.123.064168","article-title":"Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease","volume":"147","author":"Zhang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib530","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib531","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3390\/jcm8071080","article-title":"Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients","volume":"8","author":"Masana","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib532","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2016.10.004","article-title":"The Montreal-FH-SCORE: a new score to predict cardiovascular events in familial hypercholesterolemia","volume":"11","author":"Paquette","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib533","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib534","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib535","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/eurheartj\/ehx004","article-title":"Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia","volume":"38","author":"Tada","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib536","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","article-title":"Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands","volume":"357","author":"Umans-Eckenhausen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib537","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf7000","article-title":"Genetic identification of familial hypercholesterolemia within a single U.S. health care system","volume":"354","author":"Abul-Husn","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacc.2025.11.016_bib538","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.122.003816","article-title":"Familial hypercholesterolemia in the electronic medical records and genomics network: prevalence, penetrance, cardiovascular risk, and outcomes after return of results","volume":"16","author":"Dikilitas","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib539","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacc.2025.11.016_bib540","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.121.003501","article-title":"Coronary artery disease risk of familial hypercholesterolemia genetic variants independent of clinically observed longitudinal cholesterol exposure","volume":"15","author":"Clarke","year":"2022","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib541","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","article-title":"Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease","volume":"5","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib542","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.123.064168","article-title":"Association of severe hypercholesterolemia and familial hypercholesterolemia genotype with risk of coronary heart disease","volume":"147","author":"Zhang","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib543","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia","volume":"102","author":"Civeira","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib544","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117353","article-title":"Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): a cross-sectional database study in Lambeth, South London","volume":"388","author":"Molokhia","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib545","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jamacardio.2021.1301","article-title":"Limited-variant screening vs comprehensive genetic testing for familial hypercholesterolemia diagnosis","volume":"6","author":"Sturm","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib546","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41436-018-0311-2","article-title":"Recall by genotype and cascade screening for familial hypercholesterolemia in a population-based biobank from Estonia","volume":"21","author":"Alver","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib547","first-page":"1552","article-title":"Variation in the prevalence of familial hypercholesterolemia around the world","volume":"65","author":"Mathews","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib548","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjcard.2012.04.062","article-title":"Secondary causes of dyslipidemia","volume":"110","author":"Vodnala","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib549","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib550","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib551","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.11.016_bib552","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib553","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib554","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib555","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib556","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jcmg.2018.09.019","article-title":"Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy","volume":"12","author":"Miname","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib557","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib558","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib559","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib560","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib561","first-page":"354","article-title":"Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","author":"Raal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib562","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib563","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MOL.0000000000000813","article-title":"Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia","volume":"33","author":"Antoniazi","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib564","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib565","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib566","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/CIRCULATIONAHA.116.024534","article-title":"Ischemia and no obstructive coronary artery disease (INOCA): developing evidence-based therapies and research agenda for the next decade","volume":"135","author":"Bairey Merz","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib567","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","article-title":"Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry","volume":"289","author":"Duell","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib568","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients With homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib569","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib570","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib571","doi-asserted-by":"crossref","first-page":"151","DOI":"10.31083\/j.rcm2305151","article-title":"Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: a systematic review","volume":"23","author":"Wei","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib572","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","article-title":"Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia","volume":"105","author":"Gagne","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib573","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib574","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib575","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib576","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib577","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029175","article-title":"Contemporary homozygous familial hypercholesterolemia in the United States: insights from the CASCADE FH registry","volume":"12","author":"Cuchel","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib578","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib579","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib580","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib581","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib582","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a2423","article-title":"Efficacy of statins in familial hypercholesterolaemia: a long term cohort study","volume":"337","author":"Versmissen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.11.016_bib583","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2016.04.054","article-title":"Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality","volume":"68","author":"Besseling","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib584","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib585","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy, safety, and tolerability of inclisiran in patients With homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib586","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib587","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Cholesterol Treatment Trialists Collaboration. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib588","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2165\/11638240-000000000-00000","article-title":"Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis","volume":"72","author":"de Vries","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2025.11.016_bib589","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib590","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib591","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib592","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib593","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib594","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib595","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","article-title":"Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials","volume":"135","author":"Ridker","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib596","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.2337\/dc12-2455","article-title":"Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes","volume":"36","author":"Constantino","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib597","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(15)00508-2","article-title":"Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study","volume":"4","author":"Huo","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib598","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-008-1076-y","article-title":"Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database","volume":"51","author":"Mulnier","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2025.11.016_bib599","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11606-015-3556-3","article-title":"Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events","volume":"31","author":"Rana","year":"2016","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib600","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","article-title":"High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database","volume":"29","author":"Soedamah-Muthu","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib601","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1479164112436403","article-title":"Global cardiovascular disease risk assessment in United States adults with diabetes","volume":"9","author":"Wong","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib602","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib603","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib604","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib605","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib606","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.amjcard.2017.02.023","article-title":"Presence, characteristics, and volumes of coronary plaque determined by computed tomography angiography in young type 2 diabetes mellitus","volume":"119","author":"Nezarat","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib607","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib608","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib609","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib610","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib611","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib612","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2020.01.001","article-title":"Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial","volume":"14","author":"Moriarty","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib613","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib614","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib615","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib616","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.15650","article-title":"Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials","volume":"26","author":"Leiter","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib617","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2337\/db05-1423","article-title":"The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience","volume":"55","author":"Pambianco","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.11.016_bib618","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.0686","article-title":"Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood","volume":"317","author":"Dabelea","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib619","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.03.009","article-title":"Prospective association between diabetic retinopathy and cardiovascular disease: a systematic review and meta-analysis of cohort studies","volume":"25","author":"Guo","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib620","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/heartjnl-2014-305657","article-title":"Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus","volume":"100","author":"Brownrigg","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2025.11.016_bib621","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1479164113500798","article-title":"Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register","volume":"10","author":"Svensson","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib622","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejvs.2004.11.013","article-title":"Prevalence and prognostic significance of asymptomatic peripheral arterial disease in 68-year-old men with diabetes. Results from the population study 'Men born in 1914' from Malmo, Sweden","volume":"29","author":"Ogren","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jacc.2025.11.016_bib623a","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9620513","article-title":"Lower extremity peripheral arterial disease is an independent predictor of coronary heart disease and stroke risks in patients with type 2 diabetes mellitus in China","volume":"2017","author":"Pang","year":"2017","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib624a","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib623","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib624","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib625","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib626","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib627","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib628","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib629","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib630","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib631","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib632","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib633","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib634","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib635","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib636","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029216","article-title":"Long-term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo-controlled observation in the ODYSSEY OUTCOMES trial","volume":"12","author":"Goodman","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib637","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib638","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Odyssey Outcomes Committee Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib639","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib640","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib641","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","article-title":"Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial","volume":"75","author":"Bhatt","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib642","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamacardio.2019.1647","article-title":"Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease","volume":"4","author":"Fonarow","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib643","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib644","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib645","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.11.016_bib646","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcmg.2019.02.005","article-title":"Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC \u22651,000: results from the CAC Consortium","volume":"13","author":"Peng","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib647","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.120.050545","article-title":"Very high coronary artery calcium (\u22651000) and association with cardiovascular disease events, non\u2013cardiovascular disease outcomes, and mortality","volume":"143","author":"Peng","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib648","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a calcium score equate to secondary prevention?: insights from the multinational CONFIRM Registry","volume":"16","author":"Budoff","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib649","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jcmg.2011.11.014","article-title":"Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study","volume":"5","author":"Mulders","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib650","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib651","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.atherosclerosis.2022.02.006","article-title":"Coronary artery calcium scores indicating secondary prevention level risk: findings from the CAC consortium and FOURIER trial","volume":"347","author":"Dzaye","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib652","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2025.0584","article-title":"Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial","volume":"333","author":"Nerlekar","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib653","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1161\/CIRCULATIONAHA.113.003625","article-title":"Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease","volume":"129","author":"Martin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib654","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib655","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa072100","article-title":"Coronary calcium as a predictor of coronary events in four racial or ethnic groups","volume":"358","author":"Detrano","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib656","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamacardio.2016.5493","article-title":"Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death","volume":"2","author":"Carr","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib657","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.mayocp.2014.05.017","article-title":"Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort","volume":"89","author":"Tota-Maharaj","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.11.016_bib658","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcct.2023.10.001","article-title":"Accuracy of incidental visual coronary artery calcium assessment compared with dedicated coronary artery calcium scoring","volume":"17","author":"Raygor","year":"2023","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2025.11.016_bib659","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1148\/radiol.15142062","article-title":"Association of coronary artery calcification and mortality in the National Lung Screening Trial: a comparison of three scoring methods","volume":"276","author":"Chiles","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2025.11.016_bib660","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/CIRCULATIONAHA.122.062746","article-title":"Incidental coronary artery calcium: opportunistic screening of previous nongated chest computed tomography scans to improve statin rates (NOTIFY-1 Project)","volume":"147","author":"Sandhu","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib661","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib662","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jacc.2024.06.045","article-title":"Influence of subclinical atherosclerosis burden and progression on mortality","volume":"84","author":"Fuster","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib663","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib664","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ahj.2023.12.004","article-title":"Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial","volume":"269","author":"Bohula","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib665","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib666","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib667","first-page":"1476","article-title":"Ezetimibe plus a statin after acute coronary syndromes","volume":"373","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib668","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib669","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Odyssey Outcomes Committee Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib670","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1161\/CIRCULATIONAHA.116.027034","article-title":"Value of progression of coronary artery calcification for risk prediction of coronary and cardiovascular events: result of the HNR Study (Heinz Nixdorf Recall)","volume":"137","author":"Lehmann","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib671","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jacc.2005.02.089","article-title":"Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E","volume":"46","author":"Arad","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib672","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jcmg.2016.04.013","article-title":"Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT angiography study","volume":"10","author":"Shin","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib673","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib674","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jcct.2016.11.003","article-title":"2016 SCCT\/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology","volume":"11","author":"Hecht","year":"2017","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jacc.2025.11.016_bib675","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.120.011701","article-title":"Association of carotid artery plaque with cardiovascular events and incident coronary artery calcium in individuals with absent coronary calcification: the MESA","volume":"14","author":"Mehta","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib676","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamacardio.2024.5702","article-title":"Importance of age and sex in carotid artery plaque detection and cardiovascular disease risk","volume":"10","author":"Tattersall","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib677","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ehjci\/jex239","article-title":"Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans","volume":"19","author":"Sillesen","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.11.016_bib678","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.1995.03520420045036","article-title":"Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC)","volume":"273","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib679","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1542\/peds.94.6.923","article-title":"Reduction of elevated LDL-cholesterol levels of 4- to 10-year-old children through home-based dietary education","volume":"94","author":"Shannon","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2025.11.016_bib680","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajcnut.2023.10.025","article-title":"Effects of wholegrain compared to refined grain intake on cardiometabolic risk markers, gut microbiota, and gastrointestinal symptoms in children: a randomized crossover trial","volume":"119","author":"Madsen","year":"2024","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib681","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186672","article-title":"Health effects of saturated and trans-fatty acid intake in children and adolescents: systematic review and meta-analysis","volume":"12","author":"Te Morenga","year":"2017","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jacc.2025.11.016_bib682","article-title":"Statins for children with familial hypercholesterolemia","volume":"2019","author":"Vuorio","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib683","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib684","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.123.064296","article-title":"Childhood non-HDL cholesterol and LDL cholesterol and adult atherosclerotic cardiovascular events","volume":"149","author":"Wu","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib685","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib686","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jpeds.2015.02.043","article-title":"Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia","volume":"166","author":"Kusters","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib687","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib688","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf7000","article-title":"Genetic identification of familial hypercholesterolemia within a single U.S. health care system","volume":"354","author":"Abul-Husn","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jacc.2025.11.016_bib689","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpeds.2020.09.042","article-title":"Children with heterozygous familial hypercholesterolemia in the United States: data from the Cascade Screening for Awareness and Detection-FH registry","volume":"229","author":"de Ferranti","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib690","article-title":"Clinical scores fail to sufficiently identify children with familial hypercholesterolemia","author":"Schmieder","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib691","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1001\/jama.2019.4984","article-title":"Trends in levels of lipids and apolipoprotein B in US youths aged 6 to 19 years, 1999-2016","volume":"321","author":"Perak","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib692","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamapediatrics.2021.2046","article-title":"Low-density lipoprotein cholesterol trajectories and prevalence of high low-density lipoprotein cholesterol consistent with heterozygous familial hypercholesterolemia in US children","volume":"175","author":"Zhang","year":"2021","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib693","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib694","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib695","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib696","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jama.2014.8892","article-title":"Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia","volume":"312","author":"Kusters","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib697","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib698","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2109191","article-title":"Childhood cardiovascular risk factors and adult cardiovascular events","volume":"386","author":"Jacobs","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib699","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2786","article-title":"Dietary fats and atherosclerosis from childhood to adulthood","volume":"145","author":"Laitinen","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2025.11.016_bib700","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S2352-4642(20)30059-6","article-title":"Effects of 20-year infancy-onset dietary counselling on cardiometabolic risk factors in the Special Turku Coronary Risk Factor Intervention Project (STRIP): 6-year post-intervention follow-up","volume":"4","author":"Pahkala","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jacc.2025.11.016_bib701","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association","volume":"139","author":"de Ferranti","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib702","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12937-015-0077-1","article-title":"Effects of low glycaemic index\/low glycaemic load vs. high glycaemic index\/ high glycaemic load diets on overweight\/obesity and associated risk factors in children and adolescents: a systematic review and meta-analysis","volume":"14","author":"Schwingshackl","year":"2015","journal-title":"Nutr J"},{"key":"10.1016\/j.jacc.2025.11.016_bib703","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2016.08.041","article-title":"Adolescent dyslipidemia and standardized lifestyle modification: benchmarking real-world practice","volume":"68","author":"Zachariah","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib704","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jacl.2014.01.003","article-title":"Combined dyslipidemia in obese children: response to a focused lifestyle approach","volume":"8","author":"Pratt","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib705","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jpeds.2021.01.070","article-title":"Improving cardiovascular health in a pediatric preventive cardiology practice","volume":"232","author":"Gooding","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib706","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpeds.2016.08.003","article-title":"Correlates of achieving statin therapy goals in children and adolescents with dyslipidemia","volume":"178","author":"Mendelson","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib707","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamapediatrics.2023.6477","article-title":"Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: a randomized clinical trial","volume":"178","author":"Santos","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib708","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/eurjpc\/zwac025","article-title":"Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia","volume":"29","author":"Reijman","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib709","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1097\/FJC.0000000000001053","article-title":"Inclisiran: a novel agent for lowering apolipoprotein B-containing lipoproteins","volume":"78","author":"Warden","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2025.11.016_bib710","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3476(96)70188-9","article-title":"Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia","volume":"129","author":"Tonstad","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib711","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpeds.2009.08.037","article-title":"Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia","volume":"156","author":"Stein","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib712","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.2023.8867","article-title":"Screening for lipid disorders in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force","volume":"330","author":"Guirguis-Blake","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib713","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib714","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.31097","article-title":"Analysis of insulin resistance among children and adolescents in Slovenia with hypercholesterolemia after treatment with statins","volume":"5","author":"Groselj","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib715","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jacc.2025.11.016_bib717","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1602777","article-title":"Child-parent familial hypercholesterolemia screening in primary care","volume":"375","author":"Wald","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib718","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib719","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib720","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jpeds.2008.12.044","article-title":"Ezetimibe treatment of pediatric patients with hypercholesterolemia","volume":"154","author":"Clauss","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jacc.2025.11.016_bib721","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/ATVBAHA.122.317793","article-title":"Efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia: phase 3, multinational open-label study","volume":"42","author":"Bruckert","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib722","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib723","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/2327-6924.12447","article-title":"Fiber supplements and clinically proven health benefits: How to recognize and recommend an effective fiber therapy","volume":"29","author":"Lambeau","year":"2017","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1016\/j.jacc.2025.11.016_bib724","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1017\/S0007114514000750","article-title":"LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies","volume":"112","author":"Ras","year":"2014","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib726","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.114.012477","article-title":"Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease","volume":"131","author":"Navar-Boggan","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib727","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib728","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa2109191","article-title":"Childhood cardiovascular risk factors and adult cardiovascular events","volume":"386","author":"Jacobs","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib729","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib730","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/CIRCULATIONAHA.116.022335","article-title":"Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype","volume":"134","author":"Perak","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib731","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib732","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.118.037137","article-title":"Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction","volume":"139","author":"Arora","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib733","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to March 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib734","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100299","article-title":"Analysis of apoB concentrations across early adulthood and predictors for rates of change using CARDIA study data","volume":"63","author":"Wilkins","year":"2022","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib735","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jacc.2024.05.070","article-title":"Prediction of cumulative exposure to atherogenic lipids during early adulthood","volume":"84","author":"Wilkins","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib736","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.jacc.2021.08.065","article-title":"Cost-effectiveness of lipid-lowering treatments in young adults","volume":"78","author":"Kohli-Lynch","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib737","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jgs.15809","article-title":"Decision making for older adults with multiple chronic conditions: executive summary for the American Geriatrics Society guiding principles on the care of older adults with multimorbidity","volume":"67","author":"Boyd","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2025.11.016_bib738","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2018.03.022","article-title":"Multimorbidity in older adults with cardiovascular disease","volume":"71","author":"Forman","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib739","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib740","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib741","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib742","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib743","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2020.7848","article-title":"Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older","volume":"324","author":"Orkaby","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib744","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib745","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib746","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2019.11.008","article-title":"All-cause and cause-specific mortality in individuals with zero and minimal coronary artery calcium: a long-term, competing risk analysis in the Coronary Artery Calcium Consortium","volume":"294","author":"Blaha","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib747","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2016.05.084","article-title":"A simple disease-guided approach to personalize ACC\/AHA-recommended statin allocation in elderly people: the BioImage Study","volume":"68","author":"Mortensen","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib748","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jacc.2008.04.004","article-title":"Coronary artery calcium to predict all-cause mortality in elderly men and women","volume":"52","author":"Raggi","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib749","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamacardio.2017.2498","article-title":"Association of coronary artery calcium score vs age with cardiovascular risk in older adults: an analysis of pooled population-based studies","volume":"2","author":"Yano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib750","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/jgs.18312","article-title":"Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): trial design and rationale","volume":"71","author":"Joseph","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2025.11.016_bib751","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069915","article-title":"Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial)","volume":"13","author":"Zoungas","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib752","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib753","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial","volume":"152","author":"Glynn","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib754","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib755","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/11595620-000000000-00000","article-title":"Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study)","volume":"28","author":"Nakaya","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jacc.2025.11.016_bib756","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.2337\/dc06-0872","article-title":"Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"29","author":"Neil","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib757","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamainternmed.2017.1442","article-title":"Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial","volume":"177","author":"Han","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib758","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","article-title":"Central nervous system and limb anomalies in case reports of first-trimester statin exposure","volume":"350","author":"Edison","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib759","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/tera.1420500604","article-title":"Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits","volume":"50","author":"Dostal","year":"1994","journal-title":"Teratology"},{"key":"10.1016\/j.jacc.2025.11.016_bib760","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.41321","article-title":"Perinatal outcomes after statin exposure during pregnancy","volume":"4","author":"Chang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib761","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1111\/bcp.15423","article-title":"Pregnancy outcomes following maternal exposure to statins: A systematic review and meta-analysis","volume":"88","author":"Karadas","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2025.11.016_bib762","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/0026-0495(94)90061-2","article-title":"Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis","volume":"43","author":"Kroon","year":"1994","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.11.016_bib763","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/0026-0495(95)90247-3","article-title":"Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption","volume":"44","author":"Teruel","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2025.11.016_bib764","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1034\/j.1600-0412.1998.770605.x","article-title":"Pregnancy outcome in familial homozygous hypercholesterolemic females treated with long-term plasma exchange","volume":"77","author":"Beigel","year":"1998","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jacc.2025.11.016_bib765","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1210\/jc.2012-1250","article-title":"Severe hypertriglyceridemia in pregnancy","volume":"97","author":"Goldberg","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib766","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2018.05.038","article-title":"Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies","volume":"277","author":"Botha","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib767","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235839","article-title":"Historic and recent trends in county-level coronary heart disease death rates by race, gender, and age group, United States, 1979-2017","volume":"15","author":"Vaughan","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.11.016_bib768","article-title":"Unique features of dyslipidemia in women across a lifetime and a tailored approach to management","volume":"18","author":"Patel","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib769","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1016\/j.jacl.2024.05.005","article-title":"Dyslipidemia management in women of reproductive potential: an expert clinical consensus from the National Lipid Association","volume":"18","author":"Agarwala","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib770","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/tera.1420280316","article-title":"Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase","volume":"28","author":"Minsker","year":"1983","journal-title":"Teratology"},{"key":"10.1016\/j.jacc.2025.11.016_bib771","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/CIRCULATIONAHA.121.058983","article-title":"Statin use in pregnancy: is it time for a paradigm shift?","volume":"145","author":"Mauricio","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib772","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosissup.2015.02.024","article-title":"Pregnancy in homozygous familial hypercholesterolemia-importance of LDL-apheresis","volume":"18","author":"Blaha","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2025.11.016_bib773","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1744-9987.13841","article-title":"Pregnancy in homozygous familial hypercholesterolemia-a case series","volume":"26","author":"Blaha","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.jacc.2025.11.016_bib774","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.atherosclerosis.2016.10.018","article-title":"Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: seven case series and discussion","volume":"254","author":"Ogura","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib775","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jacl.2007.11.001","article-title":"Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction","volume":"2","author":"Lee","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib776","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753495X15594082","article-title":"Severe gestational hypertriglyceridemia: a practical approach for clinicians","volume":"8","author":"Wong","year":"2015","journal-title":"Obstet Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib777","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacl.2020.10.001","article-title":"Association of high maternal triglyceride levels early and late in pregnancy with adverse outcomes: a retrospective cohort study","volume":"15","author":"Xue","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib778","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2393-4-27","article-title":"Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: a case report","volume":"4","author":"Tsai","year":"2004","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.jacc.2025.11.016_bib779","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.nut.2009.04.009","article-title":"Hypertriglyceridemic acute pancreatitis during pregnancy: prevention with diet therapy and omega-3 fatty acids in the following pregnancy","volume":"25","author":"Takaishi","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.jacc.2025.11.016_bib781","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.reprotox.2005.07.014","article-title":"Colesevelam hydrochloride does not cause maternal or fetal toxicity in rats and rabbits","volume":"21","author":"Marquis","year":"2006","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jacc.2025.11.016_bib783","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2025.11.016_bib784","doi-asserted-by":"crossref","first-page":"666.e661","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia","volume":"225","author":"Costantine","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jacc.2025.11.016_bib785","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1055\/a-1798-1925","article-title":"INOVASIA study: a multicenter randomized clinical trial of pravastatin to prevent preeclampsia in high-risk patients","volume":"41","author":"Akbar","year":"2024","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jacc.2025.11.016_bib787","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.2147\/DDDT.S184053","article-title":"Transfer of rosuvastatin into breast milk: liquid chromatography-mass spectrometry methodology and clinical recommendations","volume":"12","author":"Lwin","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jacc.2025.11.016_bib788","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib789","series-title":"Regeneron Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.jacc.2025.11.016_bib790","series-title":"JUXTAPIDTM (lomitapide) [package insert]","year":"2012"},{"key":"10.1016\/j.jacc.2025.11.016_bib791","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a Scientific Statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib792","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/j.jacc.2014.08.048","article-title":"Cardiovascular disease mortality in Asian Americans","volume":"64","author":"Jose","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib793","first-page":"e41","article-title":"2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"25","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib794","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacl.2021.03.007","article-title":"Prevention of atherosclerotic cardiovascular disease in South Asians in the US: a clinical perspective from the National Lipid Association","volume":"15","author":"Kalra","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib795","article-title":"Association of acculturation with cardiovascular risk factors in Asian-American subgroups","volume":"13","author":"Li","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib796","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.7326\/M24-0801","article-title":"Cardiovascular disease mortality among Native Hawaiian and Pacific Islander adults aged 35 years or older, 2018 to 2022","volume":"177","author":"Woodruff","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib797","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIR.0000000000000071","article-title":"Status of cardiovascular disease and stroke in Hispanics\/Latinos in the United States","volume":"130","author":"Rodriguez","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib798","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000580","article-title":"Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a Scientific Statement from the American Heart Association","volume":"138","author":"Volgman","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib799","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib800","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib801","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2337\/diaclin.33.2.97","article-title":"Standards of medical care in diabetes-2015 abridged for primary care providers","volume":"33","year":"2015","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jacc.2025.11.016_bib802","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1001\/jama.2021.12531","article-title":"Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement","volume":"326","author":"Davidson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib803","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7326\/M20-8079","article-title":"Diabetes screening by race and ethnicity in the United States: equivalent body mass index and age thresholds","volume":"175","author":"Aggarwal","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib804","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jclinepi.2007.08.012","article-title":"Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis","volume":"61","author":"Lee","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib805","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2337\/dc22-1847","article-title":"Trends in the prevalence of lean diabetes among U.S. Adults, 2015-2020","volume":"46","author":"Adesoba","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib806","doi-asserted-by":"crossref","first-page":"814","DOI":"10.2337\/dc14-2071","article-title":"Optimum BMI cut points to screen asian americans for type 2 diabetes","volume":"38","author":"Araneta","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2025.11.016_bib807","article-title":"Heterogeneity in cardio-metabolic risk factors and atherosclerotic cardiovascular disease among Asian groups in the United States","volume":"7","author":"Satish","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib808","article-title":"Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels","volume":"3","author":"Dudum","year":"2024","journal-title":"JACC"},{"key":"10.1016\/j.jacc.2025.11.016_bib809","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib810","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004344","article-title":"Creatine kinase in the U.S. population: Impact of demographics, comorbidities, and body composition on the normal range","volume":"95","author":"George","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2025.11.016_bib811","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2025.11.016_bib812","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib813","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib814","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1253\/circj.CJ-12-1062","article-title":"Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study)","volume":"77","author":"Takano","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2025.11.016_bib815","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib816","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ejhf.247","article-title":"Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF","volume":"17","author":"Feinstein","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.11.016_bib817","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171168","article-title":"No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"12","author":"Al-Gobari","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2025.11.016_bib818","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","article-title":"Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis","volume":"18","author":"Bielecka-Dabrowa","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib819","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1136\/heartjnl-2022-322181","article-title":"Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model","volume":"109","author":"Sotomi","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2025.11.016_bib820","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.amjmed.2019.10.030","article-title":"Risk Factors for heart failure in the community: differences by age and ejection fraction","volume":"133","author":"Chamberlain","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib821","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/CIRCULATIONAHA.106.623199","article-title":"Navigating the crossroads of coronary artery disease and heart failure","volume":"114","author":"Gheorghiade","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib822","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","article-title":"Implications of coronary artery disease in heart failure with preserved ejection fraction","volume":"63","author":"Hwang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib823","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of heart failure: a contemporary perspective","volume":"128","author":"Roger","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib824","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/jamacardio.2021.1825","article-title":"Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction","volume":"6","author":"Rush","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib825","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.amjcard.2024.08.017","article-title":"Burden of atherosclerotic disease risk factors in patients with and without rheumatologic disease: a retrospective cohort study","volume":"230","author":"DiGregorio","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib826","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/09612033221147471","article-title":"Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis","volume":"32","author":"Bello","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.jacc.2025.11.016_bib827","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib828","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2023.09.819","article-title":"Novel imaging approaches to cardiac manifestations of systemic inflammatory diseases: JACC Scientific Statement","volume":"82","author":"Weber","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib829","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/kex038","article-title":"Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries","volume":"56","author":"Crowson","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jacc.2025.11.016_bib830","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1093\/rheumatology\/kev198","article-title":"Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis","volume":"54","author":"Kiani","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jacc.2025.11.016_bib831","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/ar2641","article-title":"Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis","volume":"11","author":"Giles","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jacc.2025.11.016_bib832","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3899\/jrheum.160110","article-title":"Cardiovascular outcomes associated with lowering low-density lipoprotein cholesterol in rheumatoid arthritis and matched nonrheumatoid arthritis","volume":"43","author":"An","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jacc.2025.11.016_bib833","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2015.08.030","article-title":"Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study","volume":"243","author":"Yu","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib834","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib835","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"2023","author":"Tunnicliffe","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib836","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib837","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib838","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib839","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib840","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S2213-8587(24)00063-9","article-title":"Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation authors' reply","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib841","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.11.016_bib842","article-title":"A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease","volume":"14","author":"Igweonu-Nwakile","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jacc.2025.11.016_bib843","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib844","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib845","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib846","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib847","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1097\/QAD.0b013e3283493fb0","article-title":"Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study","volume":"25","author":"Rasmussen","year":"2011","journal-title":"Aids"},{"key":"10.1016\/j.jacc.2025.11.016_bib848","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/COH.0000000000000227","article-title":"Immune activation and cardiovascular disease in chronic HIV infection","volume":"11","author":"Longenecker","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.jacc.2025.11.016_bib849","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1016\/j.jacc.2017.05.012","article-title":"HIV-1\u2013associated atherosclerosis: unraveling the missing link","volume":"69","author":"Kearns","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib850","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/ATVBAHA.122.318232","article-title":"Cardiovascular disease and thrombosis in HIV infection","volume":"43","author":"Perkins","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib851","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","article-title":"Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial","volume":"9","author":"Lu","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib852","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib853","series-title":"Lipitor [package insert]","year":"2007"},{"key":"10.1016\/j.jacc.2025.11.016_bib854","series-title":"Mevacor [package insert]","year":"2014"},{"key":"10.1016\/j.jacc.2025.11.016_bib855","series-title":"Livalo [package insert]","year":"2019"},{"key":"10.1016\/j.jacc.2025.11.016_bib856","series-title":"Pravachol [package insert]","year":"2022"},{"key":"10.1016\/j.jacc.2025.11.016_bib857","series-title":"Crestor [package insert]","year":"2023"},{"key":"10.1016\/j.jacc.2025.11.016_bib858","series-title":"Zocor [package insert]","year":"2014"},{"key":"10.1016\/j.jacc.2025.11.016_bib859","series-title":"Lescol, Lescol XL [package insert)","year":"2012"},{"key":"10.1016\/j.jacc.2025.11.016_bib861","series-title":"Endotext","article-title":"Lipid disorders in people with HIV. Table 5. Interaction of antiretroviral therapy and statins","author":"Sarkar","year":"2000"},{"key":"10.1016\/j.jacc.2025.11.016_bib862","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/jnci\/djaa096","article-title":"All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort","volume":"113","author":"Ramin","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jacc.2025.11.016_bib863","article-title":"Relative burden of cancer and noncancer mortality among long-term survivors of breast, prostate, and colorectal cancer in the US","volume":"6","author":"Madhav","year":"2023","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib864","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2025.11.016_bib865","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029967","article-title":"Heart disease mortality in cancer survivors: a population-based study in Japan","volume":"12","author":"Gon","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib866","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib867","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.6004\/jnccn.2018.7083","article-title":"Preventive health in cancer survivors: what should we be recommending?","volume":"16","author":"Overholser","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jacc.2025.11.016_bib868","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/ph15080919","article-title":"Statin use in cancer patients with acute myocardial infarction and its impact on long-term mortality","volume":"15","author":"Stepien","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jacc.2025.11.016_bib869","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib870","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib871","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2024.04.007","article-title":"Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials","volume":"126","author":"Felix","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib872","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1186\/s12885-018-4947-8","article-title":"Statin use in cancer survivors versus the general population: cohort study using primary care data from the UK clinical practice research datalink","volume":"18","author":"Chidwick","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jacc.2025.11.016_bib873","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.2021012788","article-title":"Targeting cholesterol homeostasis in hematopoietic malignancies","volume":"139","author":"Brendolan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2025.11.016_bib874","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/2767-9764.CRC-23-0350","article-title":"Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors","volume":"3","author":"Juarez","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jacc.2025.11.016_bib875","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3390\/cells10092488","article-title":"Statins decrease programmed death-ligand 1 (Pd-l1) by inhibiting akt and \u03b2-catenin signaling","volume":"10","author":"Lim","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jacc.2025.11.016_bib876","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1578345","article-title":"The role of statins in the regulation of breast and colorectal cancer and future directions","volume":"16","author":"Dang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacc.2025.11.016_bib877","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114197","article-title":"Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: exploratory analysis of the SPARTAN trial","volume":"211","author":"Roy","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacc.2025.11.016_bib878","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10549-020-05969-9","article-title":"Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study","volume":"185","author":"Lu","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jacc.2025.11.016_bib879","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12885-019-5493-8","article-title":"Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study","volume":"19","author":"Bowles","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jacc.2025.11.016_bib880","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hon.2438_94","article-title":"Statin use and prognosis in 12,865 non-Hodgkin lymphoma patients treated in the rituximab-era","volume":"35","author":"Branvall","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jacc.2025.11.016_bib881","doi-asserted-by":"crossref","first-page":"16859","DOI":"10.1002\/cam4.6310","article-title":"Effect of proprotein convertase subtilisin\/kexin type 9 inhibition on cancer events: a pooled, post hoc, competing risk analysis of alirocumab clinical trials","volume":"12","author":"Mohammadi","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib882","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgo.2020.04.012","article-title":"Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts","volume":"12","author":"Lund","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jacc.2025.11.016_bib883","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","article-title":"Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis","volume":"56","author":"Dattilo","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2025.11.016_bib884","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa673","article-title":"Weight loss and serum lipids in overweight and obese adults: a systematic review and meta-analysis","volume":"105","author":"Hasan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib885","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00007256-200434060-00004","article-title":"What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome","volume":"34","author":"Carroll","year":"2004","journal-title":"Sports Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib886","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib887","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome. Odyssey Outcomes Committee Investigators","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib888","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib889","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib890","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib891","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib892","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib893","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib894","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00043798-199710000-00011","article-title":"Safety and efficacy of Omacor in severe hypertriglyceridemia","volume":"4","author":"Harris","year":"1997","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.jacc.2025.11.016_bib895","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib896","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","article-title":"Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study","volume":"67","author":"Wilkins","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib897","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an Expert Clinical Consensus from the National Lipid Association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib898","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib899","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacc.2025.11.016_bib900","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib901","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.jacc.2025.11.016_bib902","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib903","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib904","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib905","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1161\/01.CIR.103.23.2828","article-title":"Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"103","author":"Bloomfield Rubins","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib906","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib907","doi-asserted-by":"crossref","first-page":"32B","DOI":"10.1016\/S0002-9149(98)00035-6","article-title":"Effects of statins on triglyceride metabolism","volume":"81","author":"Ginsberg","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib908","first-page":"S5","article-title":"The beneficial effects of modest weight loss on cardiovascular risk factors","volume":"21","author":"Van Gaal","year":"1997","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.jacc.2025.11.016_bib909","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib910","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia: current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib911","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4158\/EP-2018-0157","article-title":"Familial chylomicronemia syndrome: a clinical guide for endocrinologists","volume":"24","author":"Falko","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2025.11.016_bib912","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \"FCS score\"","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib913","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib914","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib915","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","article-title":"Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized, controlled trial","volume":"143","author":"Kalstad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib916","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a Scientific Statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib918","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","article-title":"Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists","volume":"5","author":"Davidson","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib919","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib920","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib921","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib922","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib923","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib924","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"Sturzebecher","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib925","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib926","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib927","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib928","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034493","article-title":"Association of lipoprotein (a) and standard modifiable cardiovascular risk factors with incident myocardial infarction: the Mass General Brigham Lp(a) registry","volume":"13","author":"Shiyovich","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib929","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib930","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib931","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a Scientific Statement from the American Heart Association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib932","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib933","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib934","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2025.11.016_bib935","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib936","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib937","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib938","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib939","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Odyssey Outcomes Committee Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib940","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib941","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib942","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib943","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlc.2023.06.409","article-title":"Pooled safety and efficacy of inclisiran in patients with statin intolerance (ORION-10 and ORION-11)","volume":"32","author":"McQuillan","year":"2023","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacc.2025.11.016_bib944","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacc.2025.11.016_bib945","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2025.0584","article-title":"Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial","volume":"333","author":"Nerlekar","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib946","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib947","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib948","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2025.11.016_bib949","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib950","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2025.0584","article-title":"Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: a randomized clinical trial","volume":"333","author":"Nerlekar","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib951","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib952","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib953","first-page":"CD004816","article-title":"Statins for the primary prevention of cardiovascular disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2025.11.016_bib954","article-title":"Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses","volume":"374","author":"Cai","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2025.11.016_bib955","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib956","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib957","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib958","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib959","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib960","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.11.016_bib961","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib962","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/ajg.2010.299","article-title":"Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial","volume":"106","author":"Foster","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jacc.2025.11.016_bib963","article-title":"Statin use and liver-related prognosis among patients with MASLD","volume":"7","author":"Yun","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib964","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacc.2025.11.016_bib965","article-title":"Statin use and liver-related prognosis among patients with MASLD","volume":"7","author":"Yun","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib966","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2025.11.016_bib967","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.11.016_bib968","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009835","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Qu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib969","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/fca-2021-0106","article-title":"Coenzyme Q10 supplementation for the treatment of statin-associated muscle symptoms","volume":"18","author":"Chen","year":"2022","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib970","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib971","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib973","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2025.11.016_bib974","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib975","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang","year":"2022","journal-title":"BMJ Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib976","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s12325-020-01259-4","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials","volume":"37","author":"Mu","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jacc.2025.11.016_bib977","article-title":"The efficacy and safety of inclisiran for low-density lipoprotein (LDL) in patients with atherosclerotic cardiovascular disease (ASCVD): a systematic review of randomized controlled trials","volume":"16","author":"Mirghani","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jacc.2025.11.016_bib978","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048893","article-title":"Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis","volume":"12","author":"Lin","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2025.11.016_bib979","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Bytyci","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib980","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib981","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib982","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib983","doi-asserted-by":"crossref","first-page":"e1176","DOI":"10.1161\/CIR.0000000000001233","article-title":"Patient-centered adult cardiovascular care: a Scientific Statement from the American Heart Association","volume":"149","author":"Goldfarb","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib984","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jacc.2015.01.043","article-title":"Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC\/AHA guidelines","volume":"65","author":"Martin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib985","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib986","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib987","doi-asserted-by":"crossref","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib988","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.11.016_bib989","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2025.11.016_bib990","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1016\/j.ijcard.2013.06.024","article-title":"Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels","volume":"168","author":"Tikkanen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib991","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028310","article-title":"High-intensity statin reduces the risk of mortality among chronic liver disease patients with atherosclerotic cardiovascular disease: a population-based cohort study","volume":"12","author":"Bea","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.11.016_bib992","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib993","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib994","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.11.016_bib995","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib996","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","article-title":"Lipid-lowering agents that cause drug-induced hepatotoxicity","volume":"11","author":"Bhardwaj","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib997","first-page":"605","article-title":"Statins and liver injury","volume":"9","author":"Thapar","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.jacc.2025.11.016_bib998","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bjornsson","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1001","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2014.02.010","article-title":"A clinician's guide to statin drug-drug interactions","volume":"8","author":"Kellick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pcad.2022.11.002","article-title":"Clinical conundrums involving statin drug-drug interactions","volume":"75","author":"Lamprecht","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2025.11.016_bib1003","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib1004","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17425255.2020.1822324","article-title":"Potential statin drug interactions in elderly patients: a review","volume":"16","author":"Damiani","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1005","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1006","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/jcph.2406","article-title":"Statin drug-drug interactions: pharmacokinetic basis of FDA labeling recommendations and comparison across common tertiary clinical resources","volume":"64","author":"Mease","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1007","article-title":"Lescol, Lescol XL [package insert]","year":"2012","journal-title":"Novartis Pharmaceuticals Corp"},{"key":"10.1016\/j.jacc.2025.11.016_bib1008","year":"2014","journal-title":"Merck & Co, Inc"},{"key":"10.1016\/j.jacc.2025.11.016_bib1009","year":"2014","journal-title":"Merck & Co, Inc"},{"key":"10.1016\/j.jacc.2025.11.016_bib1010","year":"2007","journal-title":"Pfizer Pharmaceutical Corp"},{"key":"10.1016\/j.jacc.2025.11.016_bib1011","year":"2019","journal-title":"Kowa Pharmaceuticals"},{"key":"10.1016\/j.jacc.2025.11.016_bib1012","year":"2022","journal-title":"Bristol-Myers Squibb"},{"key":"10.1016\/j.jacc.2025.11.016_bib1013","year":"2023","journal-title":"Aztra-Zeneca Pharmaceuticals"},{"key":"10.1016\/j.jacc.2025.11.016_bib1014","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1161\/CIR.0000000000001139","article-title":"Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association","volume":"147","author":"Mehta","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib1015","article-title":"Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention","volume":"2","author":"Elder","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1016","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/CIRCULATIONAHA.119.043429","article-title":"The use of sex-specific factors in the assessment of women\u2019s cardiovascular risk","volume":"141","author":"Agarwala","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib1017","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.jacc.2020.03.060","article-title":"Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC state-of-the-art review","volume":"75","author":"Cho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1018","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-020-00864-6","article-title":"The role of sex-specific risk factors in the risk assessment of atherosclerotic cardiovascular disease for primary prevention in women","volume":"22","author":"Freaney","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacc.2025.11.016_bib1019","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.11.016_bib1020","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"73","author":"Lloyd-Jones","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1021","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.11.016_bib1022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/0272989X211044697","article-title":"Recalibration methods for improved clinical utility of risk scores","volume":"42","author":"Mishra","year":"2022","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jacc.2025.11.016_bib1023","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/eurheartj\/ehy653","article-title":"Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies","volume":"40","author":"Pennells","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.11.016_bib1024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41512-024-00184-2","article-title":"Against reflexive recalibration: towards a causal framework for addressing miscalibration","volume":"9","author":"Swaminathan","year":"2025","journal-title":"Diagn Progn Res"},{"key":"10.1016\/j.jacc.2025.11.016_bib1025","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1026","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.jacc.2016.10.018","article-title":"Estimating longitudinal risks and benefits from cardiovascular preventive therapies among Medicare patients: the Million Hearts Longitudinal ASCVD Risk Assessment Tool: a special report from the American Heart Association and American College of Cardiology","volume":"69","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1027","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2023.19597","article-title":"Effects of the Million Hearts model on myocardial infarctions, strokes, and Medicare spending: a randomized clinical trial","volume":"330","author":"Blue","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib1028","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/jama.2023.16096","article-title":"Million Hearts cardiovascular disease risk reduction model","volume":"330","author":"Tajeu","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.11.016_bib1029","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jacc.2015.01.043","article-title":"Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention","volume":"65","author":"Martin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.11.016_bib1030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/HCO.0000000000000322","article-title":"What to say and how to say it: effective communication for cardiovascular disease prevention","volume":"31","author":"Navar","year":"2016","journal-title":"Curr Opin Cardiol"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725102544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725102544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:56:12Z","timestamp":1793631372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725102544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":1012,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0735109725102544"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the","name":"copyright","label":"Copyright"}]}}